STUDY DESIGN

In the monarchE trial, two years of adjuvant abemaciclib + endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) vs. ET alone in patients with hormone receptor-positive (HR+), human epidermal growth facto